Eisai Co., Ltd. ("the Company") and its affiliates (collectively referred to as "the Group")

List of Group Companies

(As of March 31, 2022)

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Location</th>
<th>Share Capital</th>
<th>Description of Operations (*1)</th>
<th>Voting Rights (*2)</th>
<th>Relationship Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>KAN Research Institute, Inc.</td>
<td>Kobe, Japan</td>
<td>70,000 JPY</td>
<td>Pharmaceutical R&amp;D</td>
<td>100.00%</td>
<td>The Company commissions pharmaceutical R&amp;D</td>
</tr>
<tr>
<td>Eisai Distribution Co., Ltd.</td>
<td>Kanagawa, Japan</td>
<td>60,000 JPY</td>
<td>Pharmaceutical logistics</td>
<td>100.00%</td>
<td>The Company commissions pharmaceutical logistics</td>
</tr>
<tr>
<td>Eisai R&amp;D Management Co., Ltd.</td>
<td>Tokyo, Japan</td>
<td>16,000 JPY</td>
<td>Management of pharmaceutical R&amp;D</td>
<td>100.00%</td>
<td>The Company commissions a part of management and other functions related to R&amp;D</td>
</tr>
<tr>
<td>Sunplanet Co., Ltd.</td>
<td>Tokyo, Japan</td>
<td>455,000 JPY</td>
<td>Business support services, etc.</td>
<td>85.07%</td>
<td>The Company purchases business support services, etc.</td>
</tr>
<tr>
<td>EA Pharma Co., Ltd.</td>
<td>Tokyo, Japan</td>
<td>9,145,000 JPY</td>
<td>Pharmaceutical R&amp;D / production / sales</td>
<td>60.00%</td>
<td>The Company commissions pharmaceutical R&amp;D and production / purchases pharmaceutical products *3</td>
</tr>
<tr>
<td>Arteryex Inc.</td>
<td>Tokyo, Japan</td>
<td>434,000 JPY</td>
<td>Software planning and development</td>
<td>64.42%</td>
<td>- *7</td>
</tr>
<tr>
<td>Eisai Corporation of North America</td>
<td>New Jersey, USA</td>
<td>2,266,700,000 USD</td>
<td>Americas holding company</td>
<td>100.00%</td>
<td>- *3</td>
</tr>
<tr>
<td>Eisai Inc.</td>
<td>New Jersey, USA</td>
<td>151,600,000 USD</td>
<td>Pharmaceutical R&amp;D / production / sales</td>
<td>100.00% (100.00%)</td>
<td>The Company commissions pharmaceutical R&amp;D and production / sells pharmaceutical products and API *3 *5</td>
</tr>
<tr>
<td>H3 Biomedicine Inc.</td>
<td>Massachusetts, USA</td>
<td>8,000 USD</td>
<td>Pharmaceutical R&amp;D</td>
<td>100.00% (100.00%)</td>
<td>The Company commissions pharmaceutical R&amp;D</td>
</tr>
<tr>
<td>Eisai Innovation, Inc.</td>
<td>Massachusetts, USA</td>
<td>1,000 USD</td>
<td>Management of pharmaceutical investment</td>
<td>100.00% (100.00%)</td>
<td>The Company commissions management of investment in the U.S. and Europe</td>
</tr>
<tr>
<td>Eisai Ltd.</td>
<td>Ontario, Canada</td>
<td>30,000 CAD</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
<tr>
<td>Eisai China Holdings Ltd.</td>
<td>Jiangsu, China</td>
<td>664,465 RMB</td>
<td>Chinese headquarters / holding company</td>
<td>100.00% (100.00%)</td>
<td>-   *3</td>
</tr>
<tr>
<td>Eisai China Inc.</td>
<td>Jiangsu, China</td>
<td>576,125 RMB</td>
<td>Pharmaceutical production / sales</td>
<td>100.00% (100.00%)</td>
<td>The Company sells pharmaceutical products and API *3</td>
</tr>
<tr>
<td>Eisai (Suzhou) Trading Co., Ltd.</td>
<td>Jiangsu, China</td>
<td>70,000 RMB</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>The Company sells pharmaceutical products *3</td>
</tr>
<tr>
<td>Eisai (Liaoning) Pharmaceutical Co., Ltd.</td>
<td>Liaoning, China</td>
<td>50,000 RMB</td>
<td>Pharmaceutical production / sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
<tr>
<td>Eisai Europe Ltd.</td>
<td>Hertfordshire, UK</td>
<td>184,138 GBP</td>
<td>Europe headquarters / holding company, pharmaceutical sales</td>
<td>100.00%</td>
<td>The Company commissions management and administration of pharmaceutical business *3</td>
</tr>
<tr>
<td>Eisai Ltd.</td>
<td>Hertfordshire, UK</td>
<td>46,009 GBP</td>
<td>Pharmaceutical R&amp;D / sales</td>
<td>100.00% (100.00%)</td>
<td>The Company commissions pharmaceutical R&amp;D *3</td>
</tr>
<tr>
<td>Eisai Manufacturing Ltd.</td>
<td>Hertfordshire, UK</td>
<td>38,807 GBP</td>
<td>Pharmaceutical R&amp;D / production</td>
<td>100.00% (100.00%)</td>
<td>The Company sells pharmaceutical products and API / is commissioned pharmaceutical R&amp;D *3</td>
</tr>
<tr>
<td>Eisai GmbH</td>
<td>Frankfurt, Germany</td>
<td>7,669 EUR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
<tr>
<td>Eisai S.A.S.</td>
<td>Paris, France</td>
<td>19,500 EUR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
<tr>
<td>Eisai B.V.</td>
<td>Amsterdam, Netherlands</td>
<td>540 EUR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
<tr>
<td>Eisai Farmaceutica S.A.</td>
<td>Madrid, Spain</td>
<td>4,000 EUR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
<tr>
<td>Eisai S.r.l.</td>
<td>Milan, Italy</td>
<td>3,500 EUR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
<tr>
<td>Eisai Pharma AG</td>
<td>Zurich, Switzerland</td>
<td>3,000 CHF</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
<tr>
<td>Eisai AB</td>
<td>Stockholm, Sweden</td>
<td>10,000 SEK</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
</tr>
</tbody>
</table>
In August 2021, Eisai Europe Ltd. established Eisai Israel Ltd.

Notes:
1. “Description of Operations” indicates the segment applicable to the respective entity.
2. Voting rights (%): Figures in parentheses show percentage indirectly owned by the Company.
4. Hi-Eisai Pharmaceutical Inc. is considered to be a consolidated subsidiary as the Company holds effective control over its operation even though the Company's voting rights do not exceed 50%.
5. Eisai Inc. is the only subsidiary whose revenue to external customers exceeds 10% of consolidated revenue.
6. In August 2021, Eisai Europe Ltd. established Eisai Israel Ltd.
7. In March 2022, the Company acquired shares of Arteryex Inc. and made it a consolidated subsidiary in order to strengthen and rapidly expand its digital solution business base.

<table>
<thead>
<tr>
<th>Company Name</th>
<th>Location</th>
<th>Share Capital</th>
<th>Description of Operations (*1)</th>
<th>Voting Rights (%)</th>
<th>Relationship</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eisai Farmacéutica, Unipessoal Lda.</td>
<td>Lisbon, Portugal</td>
<td>1,250 EUR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Eisai SA/NV</td>
<td>Brussels, Belgium</td>
<td>2,001 EUR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Eisai GesmbH</td>
<td>Vienna, Austria</td>
<td>2,000 EUR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Limited Liability Company Eisai</td>
<td>Moscow, Russia</td>
<td>4,000 RUB</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Eisai Israel Ltd.</td>
<td>Tel Aviv, Israel</td>
<td>5,000 ILS</td>
<td>Pharmaceutical business</td>
<td>100.00% (100.00%)</td>
<td>-</td>
<td>*6</td>
</tr>
<tr>
<td>Eisai Asia Regional Services Pte. Ltd.</td>
<td>Singapore</td>
<td>34,469 SGD</td>
<td>Asia holding company</td>
<td>100.00%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Eisai (Singapore) Pte. Ltd.</td>
<td>Singapore</td>
<td>300 SGD</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>The Company sells pharmaceutical products</td>
<td></td>
</tr>
<tr>
<td>Eisai Clinical Research Singapore Pte. Ltd.</td>
<td>Singapore</td>
<td>10 SGD</td>
<td>Pharmaceutical R&amp;D</td>
<td>100.00% (100.00%)</td>
<td>The Company commissions pharmaceutical R&amp;D</td>
<td></td>
</tr>
<tr>
<td>Eisai Taiwan Inc.</td>
<td>Taipei, Taiwan</td>
<td>270,000 TWD</td>
<td>Pharmaceutical sales</td>
<td>100.00%</td>
<td>The Company sells pharmaceutical products</td>
<td></td>
</tr>
<tr>
<td>Eisai (Thailand) Marketing Co., Ltd.</td>
<td>Bangkok, Thailand</td>
<td>103,000 THB</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>The Company sells pharmaceutical products</td>
<td></td>
</tr>
<tr>
<td>PT Eisai Indonesia</td>
<td>Jakarta, Indonesia</td>
<td>1,630,000 IDR</td>
<td>Pharmaceutical production / sales</td>
<td>100.00%</td>
<td>The Company sells pharmaceutical products and API</td>
<td></td>
</tr>
<tr>
<td>Eisai (Malaysia) Sdn. Bhd.</td>
<td>Petaling Jaya, Malaysia</td>
<td>470 MYR</td>
<td>Pharmaceutical sales</td>
<td>100.00% (5.74%)</td>
<td>The Company sells pharmaceutical products</td>
<td></td>
</tr>
<tr>
<td>Hi-Eisai Pharmaceutical Inc.</td>
<td>Manila, Philippines</td>
<td>122,000 PHP</td>
<td>Pharmaceutical sales</td>
<td>50.00% (1.45%)</td>
<td>The Company sells pharmaceutical products</td>
<td>*4</td>
</tr>
<tr>
<td>Eisai (Hong Kong) Co., Ltd.</td>
<td>Hong Kong</td>
<td>500 HKD</td>
<td>Pharmaceutical sales</td>
<td>100.00% (10.00%)</td>
<td>The Company sells pharmaceutical products</td>
<td></td>
</tr>
<tr>
<td>Eisai Korea Inc.</td>
<td>Seoul, South Korea</td>
<td>3,512,000 KRW</td>
<td>Pharmaceutical sales</td>
<td>100.00%</td>
<td>The Company sells pharmaceutical products</td>
<td></td>
</tr>
<tr>
<td>Eisai Pharmaceuticals India Pvt. Ltd.</td>
<td>Andhra Pradesh, India</td>
<td>2,708,324 INR</td>
<td>Pharmaceutical R&amp;D / production / sales</td>
<td>100.00% (11.08%)</td>
<td>The Company commissions pharmaceutical R&amp;D and production / sells API / purchases pharmaceutical products</td>
<td>*3</td>
</tr>
<tr>
<td>Eisai Australia Pty. Ltd.</td>
<td>Sydney, Australia</td>
<td>4,000 AUD</td>
<td>Pharmaceutical sales</td>
<td>100.00%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Eisai Laboratórios Ltda.</td>
<td>São Paulo, Brazil</td>
<td>87,899 BRL</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Eisai Laboratorios S. de R.L. de C.V.</td>
<td>Mexico City, Mexico</td>
<td>3 MXN</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Eisai New Zealand Ltd.</td>
<td>Auckland, New Zealand</td>
<td>2,050 NZD</td>
<td>Pharmaceutical sales</td>
<td>100.00% (100.00%)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Eisai Vietnam Co., Ltd.</td>
<td>Ho Chi Minh, Viet Nam</td>
<td>20,781,000 VND</td>
<td>Pharmaceutical business</td>
<td>100.00%</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Other—2 companies</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

(Associated Companies Accounted for Using the Equity Method)

<table>
<thead>
<tr>
<th>Unit=thousand</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
</tr>
<tr>
<td><strong>Operating Profit</strong></td>
</tr>
<tr>
<td><strong>Profit for the year</strong></td>
</tr>
<tr>
<td><strong>Total Equity</strong></td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
</tr>
</tbody>
</table>

Notes:
*1. “Description of Operations” indicates the segment applicable to the respective entity.
*2. Voting rights (%): Figures in parentheses show percentage indirectly owned by the Company.
*4. Hi-Eisai Pharmaceutical Inc. is considered to be a consolidated subsidiary as the Company holds effective control over its operation even though the Company’s voting rights do not exceed 50%.
*5. Eisai Inc. is the only subsidiary whose revenue to external customers exceeds 10% of consolidated revenue reported in the consolidated financial statements for the fiscal year ended March 31, 2022. Key financial results (in Japanese yen) of Eisai Inc. are as follows:

<table>
<thead>
<tr>
<th>Unit=millon</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bracco-Eisai Co., Ltd.</strong></td>
</tr>
<tr>
<td><strong>Unlimit Health Limited</strong></td>
</tr>
</tbody>
</table>